ArticleJournal of managed care & specialty pharmacy2021

The effectiveness and value of nadofaragene firadenovec, oportuzumab monatox, and pembrolizumab for BCG-unresponsive non-muscle-invasive bladder cancer.

Molly Beinfeld et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.